BMRN
USDBioMarin Pharmaceutical Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$52.560
Kõrge
$52.760
Madal
$51.800
Maht
2.96M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
10.1B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.34M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88
Bernstein analyst William Pickering maintains BioMarin Pharmaceutical with a Outperform and lowers the price target from $95 to $88.
Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
Truist Securities analyst Joon Lee maintains BioMarin Pharmaceutical with a Buy and lowers the price target from $90 to $80.
Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70
Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $90 to $70.
Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80
Barclays analyst Gena Wang maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $86 to $80.
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical with a Neutral and lowers the price target from $60 to $55.
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $104 to $98.
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with...
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.